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Edited by Frances ShannonAbstract We previously demonstrated that human hepatocellu-
lar carcinoma-derived HuH-7 cells stimulated with interleukin-
1b (IL-1b) produce a1-acid glycoprotein (AGP) with increased
amounts of sialyl Lewis X (sLeX) antigen, although the mecha-
nism remained obscure. Here, we report our investigation of the
mechanism. sLeX expression on HuH-7 cells was induced 2.5
times more after 48 h stimulation with 100 U/mL IL-1b com-
pared with control, as indicated by anti-sLeX antibody binding.
Furthermore, expression of 2,3-sialylated N-acetyllactosamine
increased gradually up to 48 h after IL-1b stimulation; this
preceded the increase in sLeX expression. Increases in a2,3-sial-
yltransferase activity also preceded increases in a1,3-fucosyl-
transferase activity. Furthermore, mRNA levels of ST3Gal IV,
FUT IV and VI in HuH-7 cells stimulated with IL-1b were in-
creased at 2–4 h, while increases in FUT VI mRNA level oc-
curred gradually after 24 h. IL-1b-induced sLeX expression on
HuH-7 cells was suppressed by transfection of gene-speciﬁc
small interference RNAs against FUT VI and ST3Gal IV but
not against FUT IV and ST3Gal III. These data results that
IL-1b induces expression of sLeX on HuH-7 cells by enhanced
expression of FUT VI and ST3Gal IV gene.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The acute-phase response is an early and immediate reaction
to tissue injury, infection and inﬂammation that is important
to innate and natural immunity [1]. During the acute-phase re-
sponse, hepatocytes secrete several acute-phase proteins into
the serum, including type I proteins such as C-reactive protein,
a1-acid glycoprotein (AGP), and serum amyloid A, and type II
proteins such as haptoglobin, a1-antichymotrypsin, and ﬁbrin-
ogen; this is a response to the pro-inﬂammatory cytokines
interleukin 1b (IL-1b), tumor necrosis factor a (TNFa) and
IL-6 via signaling pathways for the activation and transloca-
tion of nuclear factor (NF) jB, activating protein-1 (AP-1),
and NF-IL-6 [2].Abbreviations: sLeX, sialyl Lewis X; IL-1b, interleukin-1b; MAA,
Maackia amurensis agglutinin; siRNA, small interference RNA
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doi:10.1016/j.febslet.2006.09.073AGP, a heavily glycosylated protein, is a major acute-phase
protein that has various immunomodulating eﬀects that have
been shown to depend mostly on carbohydrate composition
[3–5]. Diﬀerent AGP glycoforms with varying bi-, tri-, and
tetra-antennary structures, degree of a1,3-fucosylation, or type
of sialylation, have been demonstrated in a number of
pathological and physiological states [6]. a1,3-Fucosylation
of the N-glycans forms sialyl Lewis X (sLeX) antigen,
Neu5Aca2,3 Galb1,4(Fuca1,3)GlcNAc-R. Increased a1,3-
fucosylated N-glycan structures on AGP have been reported
in patients with inﬂammation [7,8], rheumatoid arthritis [9],
and diabetes mellitus [10]. The N-glycan composition at ﬁve
N-glycosylation sites of AGP [11] and their alteration in
inﬂammation [12] have been also investigated.
SLeX expressed on leukocytes is an important ligand for E-
selectin on vascular endothelial cells; it is induced by stimula-
tion with IL-1b, TNFa and other inﬂammatory mediators. A
mild interaction between sLeX antigen on leukocytes and
E-selectin on vascular endothelial cells triggers the inﬁltration
of leukocytes into inﬂammatory sites [13]. AGP’s anti-inﬂam-
matory and immuno-modulatory roles in inﬂammation mostly
depend on its N-glycans, especially its sLeX-expressed N-gly-
cans. Glycans in serum can modulate cell-to-cell interactions
and cellular signaling, so it is pathophysiologically important
to clarify the mechanism for alteration of glycans in serum gly-
coproteins.
We previously reported that HuH-7 cells stimulated with
IL-1b as an in vitro inﬂammatory model produce increased
amounts of sLeX antigen on AGP [14], although the
mechanism remained obscure. Here, we have clariﬁed the
mechanism by determining time-dependent expression of
sLeX and its precursor a2,3-sialylated N-acetyllactosamine
(Neu5Aca2,3 Galb1,4GlcNAc-R) on the cells; glycosyltrans-
ferase activities and mRNA expression in the cells; and
estimating the eﬀects of knock-down of speciﬁc glycosyltrans-
ferase mRNA expression with small interference RNA
(siRNA).2. Materials and methods
2.1. Cells and culture condition
A human hepatocellular carcinoma cell line HuH-7, a human adeno-
carcinoma cell line Colo205 and a human acute promyelocytic cell line
HL-60 were obtained from the Japanese Collection of Research Biore-
sources (JCRB, Tokyo, Japan). HuH-7 and Colo205 cells were cul-
tured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Nissui
Pharmaceutical Co., Tokyo, Japan) and HL-60 cells were cultured in
RPMI 1640 medium (Nissui). These media were supplemented with
10% heat-inactivated fetal bovine serum (FBS) (JRH Biosciences,blished by Elsevier B.V. All rights reserved.
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Osaka, Japan), 100 U/mL penicillin (Banyu Pharmaceutical Co., To-
kyo, Japan) and 100 lg/mL streptomycin (Meiji Seika, Tokyo, Japan)
in a humidiﬁed atmosphere containing 5% CO2 at 37 C.
2.2. Determination of sLeX and a2,3-sialylated N-acetyllactosamine
expression on HuH-7 cells
HuH-7 cells (200 lL, 4.8 · 104 cells/mL) incubated overnight at 37 C
in a 96-well culture plate (Corning Inc., Nagog Park Acton, MA) were
treated with 0, 10, 100, 200 and 400 U/mL IL-1b, IL-6 and TNFa for
48 h at 37 C or with 100 U/mL IL-1b for 0–48 h at 37 C. The cells were
ﬁxed with 1% formalin in phosphate-buﬀered saline (PBS) for 1 h and
washed three times with PBS. The ﬁxed cells were incubated with
100 lL of 1 lg/mL anti-sLeX antibody (mouse IgM, CSLEX-1)
(American Type Culture Collection, Manassas, VA) and biotin-conju-
gated Maackia amurensis agglutinin (MAA) (EY Laboratories Inc.,
San Mateo, CA) in PBS containing 1% bovine serum albumin (BSA)
and 0.1%NaN3 for 1 h and washed three times with PBS. The cells were
further incubatedwith 100 lLof 1 lg/mLperoxidase (POD)-conjugated
anti-mouse IgG + IgM antibody (Jackson Immuno Research Lab.,
West Grove, PA) for sLeX and POD-conjugated streptavidin (Nacalai
Tesk, Osaka, Japan) for a2,3-sialylated N-acetyllactosamine in 1%
BSA-PBS for 1 h and washed three times with PBS. POD activities were
determined by incubating with 100 lL of TMB 1Component HRP Sub-
strate (Bio FxLab., OwingsMills,MD).After adding 100 lLof 1 mol/L
H2SO4, absorbance was measured at 450 nm using a Model MPR-A4i
micro-plate reader (Tosoh Co., Tokyo, Japan).2.3. Assay for glycosyltransferase activities
HuH-7 cells (5 · 104 cells/mL, 10 mL) precultured in 10% FBS-
DMEM in a dish (100 mm i.d.) overnight were stimulated with
100 U/mL IL-1b for 0 to 72 h at 37 C. The cells were homogenized
in 250 lL 1% Triton-X in 10 mmol/L Tris–HCl (pH 7.0) 10 s 3· on
ice by using a VP-5 s sonicator (Taitec Co., Koshigaya, Japan). After
centrifugation at 10000 rpm for 10 min, the concentration of protein in
the supernatant was adjusted to 10 mg/mL by a modiﬁed Lowry
method using BSA as a calibrator.
Sialyltransferase (ST) and fucosyltransferase (FT) activities were
determined by high-performance liquid chromatography (HPLC)
using 7-hydroxycoumarin-3-carboxylic acid (CM)-tagged substrates
as described by Higai et al. [15].
The ST assaymixture comprised 100 mmol/LHEPES buﬀer (pH 7.5),
0.5 mmol/L Galb1,4GlcNAc-CM, 0.5 mmol/L CMP-Neu5Ac (Sigma
Aldrich Co., Chicago, IL), 10 mmol/L MnCl2 and cell homogenates
(100 lg protein) in a total volume of 20 lL. The mixture was incubated
for 2 h at 37 C. The FT assay mixture comprised 100 mmol/L HEPES
buﬀer (pH 7.5), 30 mmol/L MnCl2, 1.0 mmol/L GDP-Fuc (Sigma
Aldrich), 1.0 mmol/L Neu5Aca2,3 Galb1,4GlcNAc-CM and cell
homogenates (100 lg protein) in a total volume of 20 lL. The mixture
was incubated for 8 h at 37 C. Neu5Aca2,3 Galb1,4GlcNAc-CM was
enzymatically prepared from Galb1,4GlcNAc-CM using the reaction
of a2,3-sialyltransferase (rat liver) (Boehringer Ingelheim, Ingelheim,
Germany) and CMP-Neu5Ac.
The FT and ST reaction mixtures, diluted with 100 lL distilled
water, were denatured by boiling for 3 min and centrifuged at
16000 · g for 3 min. Aliquots were injected onto a Wakopak Handy-
ODS column (4.6 i.d. ·150 mm, Wako) at 55 C and the enzymatic
products were separated from excess substrate at a ﬂow rate of
1.0 mL/min using mobile phases of 0.05% tetrabutylammonium chlo-
ride (Sigma Aldrich) and 7% (v/v) acetonitrile in 10 mmol/L ammo-
nium acetate (pH 6.0) for Galb1,4GlcNAc-CM (ST) and 5% (v/v)
acetonitrile in 10 mmol/L ammonium acetate (pH 6.0) for Neu5Aca2,3
Galb1,4 GlcNAc-CM (FT). The eluent was monitored by a Model FS-
8020 ﬂuorescence detector (Tosoh) at Ex 330 nm and Em 450 nm. The
peak areas of the enzymatic products were calculated using a Model
LC-8020 Multi Station system (Tosoh).
2.4. RT-PCR
Total cellular RNA was extracted from Colo205, HL-60 and HuH-7
cells treated with 100 U/mL IL-1b for 0 to 48 h at 37 C using TRIzol
reagent (Invitrogen Co., Carlsbad, CA). The ﬁrst strand cDNA
(20 lL) was synthesized from 5 lg of total RNA using ReverTra Ace
reverse transcriptase (Toyobo Co., Osaka, Japan) and oligo (dT)20
primers followed by DNase I treatment according to the manufac-turer’s instructions. cDNA (1 lL) was subjected to a PC-812 thermal
cycler (Astec Co., Fukuoka, Japan) using KOD-Dash (Toyobo) and
the speciﬁc primer pairs according to the manufacturer’s instructions.
Cycling conditions were 95 C for 10 min, followed by 40 cycles of
95 C for 30 s, 63 C for 60 s, and 72 C for 60 s.
Each gene was ampliﬁed using the speciﬁc primers: 5 0-CCACC-
CATGGCAAAT TCCATGGCA-3 0 (sense) and 5 0-TCTAGACGGC-
AGGTCAGGTCCACC-3 0 (antisense) for GAPDH (GenBank acces-
sion no. M33197); 5 0-CAAGAAGCCTTGAAGGACTATG-3 0 (sense)
and 5 0-AAAACGCTAGCTCGGTGTCCCGAT-3 0 (antisense) for
N-acetylglucosamide b1,4-galactosyltransferase I(GalT I, X13223);
5 0-TGAGACTGAATTCAGCACCAG-3 0 (sense) and 5 0-TCAGATG-
CCACTGCTTAGATC-30 (antisense) for b-galactoside a2,3-sialyl-
transferase 3 (ST3Gal III, NM_006279); 5 0-ACACACT CCTCGTCC-
TGGTAGCT-3 0 (sense) and 5 0-CTACAGCTCTTGCCAGGTCA-
GAA-3 0 (antisense) for b-galactoside a2,3-sialyltransferase 4 C (ST3Gal
IV, NM_006278); 5 0-CTGCTGGTGGCTGTGTGTTTCTTCTCC-
TAC-3 0 (sense) and 5 0-CAGCCAGCCGTAGGGCGTGAAGAT-
GTCGGA-30 (antisense) for b-galactoside a3(4)-L-fucosyltransferase
3, (FUT III, NM_000149) and a1,3-fucosyltransferase 5 (FUT V,
NM_002034); 5 0-GGTGCCCGAAATTGGGCTCCTGCACAC-3 0
(sense) and 50-CCAGAAGGAGGTGATGTGGACAGCGTA-30
(antisense) for a1,3-fucosyltransferase 4 (FUT IV, NM_002033);
5 0-CTCAAGACGATCCCACTGTGTAC-3 0 (sense) and 5 0-CAG-
CCAGCCGTAGGGCGTGAAGATGTCGGA-3 0 (antisense) for a1,
3-fucosyltransferase 6 (FUT VI, NM_000150); 5 0-TGCCACCTG-
AGTGCCAACCGAAGCCTGCTG-3 0 (sense) and 5 0-GGGCA-
CAAAGATGTCCGAGTCGCGCCGGTA-3 0 (antisense) for a1,
3-fucosyltransferase 7 (FUT VII, NM_004479); 5 0-CAGTGGACT-
CAGGCAATGATG-3 0 (sense) and 5 0-CAGCCACAGGCAGCA-
TGACATACTTC-3 0 (antisense) for haptoglobin (HP, NM_005143),
respectively. Primer sequences were designed using DNASIS PRO ver.
2.02 software (Hitachi Co., Tokyo, Japan) and the speciﬁcities were
ascertained by BLAST search from the DNA Data Bank of Japan
(http://www.ddbj.nig.ac.jp/welcom-j.html). PCR products were sepa-
rated on 1.5% TAE-agarose and visualized using 0.05% ethidium bro-
mide staining.2.5. Real-time PCR determination for ST3Gal III, ST3Gal IV, FUT IV
and FUT VI mRNAs
Total RNA was extracted from HuH-7 cells treated with 100 U/mL
IL-1b for 0–48 h at 37 C using Trizol according to the manufacturer’s
instructions. cDNA (5 lL) was submitted to quantitative real-time
PCRusing SYBR-Green PCRMasterMix (Toyobo) and theABI Prism
7000 Detection system (Applied Biosystems, Foster, CA) in a 96-well
plate according to themanufacturer’s instructions. PCRconditionswere
95 C for 1 min, followed by 40 cycles of 95 C for 15 s, 60 C for 60 s,
and 72 C for 60 s for GAPDH, ST3Gal III and FUT VI mRNAs.
The levels of ST3Gal IV and FUT IV mRNAs were determined by
touchdown PCR, the conditions for which were 95 C for 10 min, fol-
lowed by 2 cycles of 95 C for 60 s, 70 C for 60 s, and 72 C for 60 s, 2
cycles of 95 C for 60 s, 67 C for 60 s, and 72 C for 60 s, 2 cycles of
95 C for 60 s, 64 C for 60 s, and 72 C for 60 s, 40 cycles of 95 C for
60 s, 62 C for 60 s, and 72 C for 60 s. The amount of each glycosyl-
transferase transcript was normalized to GAPDH mRNA levels. The
speciﬁc primers used were 5 0-CAGCCTCAAGATCATCAGCA-30
(sense) and 5 0-ACAGTCTTCTGGGTGGCAGT-30 (antisense) for
GAPDH, 5 0-GGTGGCAGTCGCAGGATTT-30 (sense) and 5 0-
CATGCGAACGGTCTCATAGTAGTG-3 0 (antisense) for ST3Gal
III, 5 0-CGGGTGCGAAAGGGTTT-3 0 (sense) and 5 0-GAGA-
ATCCCAATCTGTTTAGGA-3 0 (antisense) for ST3Gal IV, 5 0-ACA-
ACTGTTCCCGATTCACGTT-3 0 (sense) and 5 0-AGGCTGTGAG-
GAATCCAAACAA-3 0 (antisense) for FUT IV, and 5 0-CAAAGCCA-
CATCGCATTGAA-30 (sense) and 5 0-ATCCCCGTTGCAGAACCA-
3 0 (antisense) for FUTVI. Primer sequences were designed using Primer
Express software ver. 2.0.0 (Applied Biosystems) and the speciﬁcities
were ascertained by BLAST search from the DNAData Bank of Japan
(http://www.ddbj.nig.ac.jp/welcom-j.html).2.6. Transfection of ST3Gal III, ST3Gal IV, FUT IV and FUT VI gene-
speciﬁc siRNAs into HuH-7 cells
Silencer Pre-designed siRNA (Ambion, Austin, TX) was transfected
into HuH-7 cells using LipofectAMINE2000 (Invitrogen) as follows.
HuH-7 cells (5 · 104 cells/well) were incubated overnight at 37 C in
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(10 pmol) in 25 lL serum-free DMEM was mixed with another
25 lL serum-free DMEM in addition to 0.5 lL LipofectAMINE2000
reagent and left for 5 min. After incubation for 20 min at room temper-
ature, the DNA-LipofectAMINE2000 complex thus prepared was
added to the cell suspension in the well. After 24 h of incubation, the
medium was replaced by 10% FBS-DMEM. The gene-speciﬁc
siRNA-transfected cells were stimulated with 100 U/mL IL-1b for
48 h at 37 C and sLeX expression was determined as described above.
The gene-speciﬁc siRNAs used were for ST3Gal III (siRNA
ID#:112419), ST3Gal IV (siRNA ID#:111668), FUT IV (siRNA
ID#:111078), and FUT VI (siRNA ID#:8020).Fig. 2. CSLEX-1 and MAA binding to HuH-7 cells stimulated with
IL-1b. HuH-7 cells were treated with 100 U/ml IL-1b for 0, 10, 24, 38,
and 72 h and sLeX (A) and a2,3-sialylated N-acetyllactosamine (B)
expression on the cells was determined using anti-sLeX and MAA-
biotin followed by POD-conjugated secondary antibody and POD-
conjugated streptavidin, respectively. Each value is shown relative to
1.0 at 0 h. The data from three independent experiments are included3. Results
3.1. SLeX expression on HuH-7 cells stimulated with
pro-inﬂammatory cytokines IL-1b, IL-6 and TNFa
HuH-7 cells were incubated with 0–400 U/mL IL-1b, IL-6
and TNFa for 48 h at 37 C and the sLeX expression levels
on the cell surfaces determined using CSLEX-1. As shown in
Fig. 1, sLeX expression was induced approximately 2.5-fold
on HuH-7 cells after 48 h of 100 U/mL IL-1b stimulation;
however, IL-6 and TNFa induced sLeX expression only
slightly even at the highest concentration of 400 U/mL.
3.2. a2,3-Sialylated N-acetyllactosamine and sLeX expression
on HuH-7 cells stimulated with IL-1b
To investigate whether expression of a2,3-sialylated N-acet-
yllactosamine, a sLeX precursor, was induced by IL-1b, HuH-
7 cells were incubated with 100 U/mL IL-1b for 0–48 h at
37 C, and then a2,3-sialylated N-acetyllactosamine and sLeX
expression levels were determined using MAA and CSLEX-1,
respectively (Fig. 2). a2,3-Sialylated N-acetyllactosamine in-
creased gradually for periods up to 48 h after IL-1b stimula-
tion, while sLeX expression was induced after 24 h andFig. 1. sLeX expression on HuH-7 cells stimulated with the pro-
inﬂammatory cytokines IL-1b, IL-6 and TNFa. HuH-7 cells were
treated with 10, 100, 200 and 400 U/ml IL-1b, IL-6 and TNFa for 48 h
and sLeX expression on the cells was determined using anti-sLeX
(CSLEX-1) and POD-conjugated secondary antibodies. Each value
includes the data from three independent experiments; error bars
deﬁne the standard error of each data set. Asterisks (*) indicate
signiﬁcant diﬀerence (P < 0.05) compared with unstimulated control
(–).
at each time point; error bars deﬁne the standard error of each data set.
Asterisks (*) indicate signiﬁcant diﬀerence (P < 0.05) compared with
0 h.gradually increased thereafter, reaching its maximum after
48 h or more. Thus, IL-1b induced an increase in a2,3-sialy-
lated N-acetyllactosamine expression on HuH-7 cells that pre-
ceded the increase in sLeX expression.
3.3. a2,3-Sialyltransferase and a1,3-fucosyltransferase activities
in HuH-7 cells stimulated with IL-1b
To clarify whether IL-1b-induced sLeX and sialyllactos-
amine expression on HuH-7 cells was involved in glycosyl-
transferase activities, HuH-7 cells were treated with 100 U/ml
IL-1b for periods of up to 72 h and a2,3-ST and a1,3-FT
activities in cell lysates were determined using CM-tagged
substrates (Fig. 3). a2,3-ST activities against Galb1,4Glc-
NAc-CM reached a maximum after 24 h of IL-1b stimulation
and remained constant for 72 h. In contrast, a1,3-FT activities
against Neu5Aca2,3 Galb1,4GlcNAc-CM gradually increased
after IL-1b stimulation, reaching a maximum (1.7-fold) after
72 h stimulation.
3.4. Expression levels of glycosyltransferase mRNAs involved
in sLeX synthesis in HuH-7 cells stimulated with IL-1b
HuH-7 cells were stimulated with 100 U/mL IL-1b for 0–
48 h at 37 C and expression of glycosyltransferase mRNAs in-
volved in sLeX synthesis, including b1,4-galactosyltransferase
Fig. 3. a2,3-Sialyltransferase and a1,3-fucosyltransferase activities in
HuH-7 cells stimulated with IL-1b. HuH-7 cells were treated with
100 U/ml IL-1b for 0, 24, 48, and 72 h and a2,3-ST (A) and a1,3-FT
(B) activities in cell lysates were determined using 7-hydroxycoumarin-
3-carboxylic acid-tagged Galb1-4GlcNAc and Neu5Aca2-3 Galb1-
4GlcNAc, respectively. The data from three independent experiments
are included at each time point; error bars deﬁne the standard errors of
each data set. Asterisks (*) indicate signiﬁcant diﬀerence (P < 0.05)
compared with 0 h.
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(ST3Gal III and IV), and an acute-phase reactant, haptoglo-
bin, were determined by RT-PCR using speciﬁc primer sets
(Fig. 4). Haptoglobin mRNA levels had increased after 4 h
of IL-1b stimulation, showing that IL-1b signaling was trans-
mitted into the cells. ST3Gal IV and FUT IV mRNA expres-
sion levels reached their maxima after 4 h of IL-1b stimulation,
then gradually decreased to reach baseline after 10 h. How-
ever, FUT VI mRNA expression levels remained unchanged
until 10 h, then gradually increased to reach the maximum
level after 48 h. The rate of increase of FUT VI mRNA expres-
sion was slower than that of haptoglobin. In contrast, GalT I
and ST3Gal III mRNA levels were not altered by IL-1b stim-
ulation. mRNA expression of FUT III and V in Colo205 cells
and FUT VII in HL-60 cells were clearly detected by RT-PCR
but levels of these mRNA expression remained below the
detection limit of RT-PCR in HuH-7 cells.
To estimate the minute alterations in FUT IV and VI, and
ST3Gal III and IV transcripts in HuH-7 cells stimulated withIL-1b, we determined their mRNA levels by real-time PCR
(Fig. 5). The mRNA expression levels were normalized to
GAPDH mRNA and each ratio of glycosyltransferase mRNA
to GAPDH mRNA was corrected to 1.0 at 0 h. Although
changes in ST3Gal III were insigniﬁcant, ST3Gal IV and
FUT IV transcript levels were increased (3.2- and 1.7-fold,
respectively) after 4 h of IL-1b stimulation, then gradually de-
creased to reach baseline after 48 h. In contrast, FUT VI
mRNA levels did not increase until 10 h of IL-1b stimulation
then gradually increased to reach a 2.2-fold maximum at
48 h. These results show two patterns of increasing mRNAs:
early (ST3Gal IV and FUT IV) and slow (FUT VI).3.5. IL-1b induced sLeX expression on HuH-7 cells transfected
with ST3Gal III, IV, FUT IV and VI gene-speciﬁc siRNAs
To clarify whether IL-1b induced sLeX expression on HuH-
7 cells by ST3Gal III and IV and FUT IV and VI, HuH-7 cells
were transfected with gene-speciﬁc siRNA and stimulated with
IL-1b (Fig. 6). We ascertained mRNA expression by RT-PCR
to estimate whether siRNAs against glycosyltransferase genes
can be inhibited in a gene-speciﬁc manner. After transfection
with siRNA and IL-1b stimulation, the mRNA expression of
each glycosyltransferase in HuH-7 cells was speciﬁcally
knocked down, by 72 ± 11% inhibition for FUT IV,
72 ± 15% for FUT VI, 66 ± 11% for ST3Gal III and
69 ± 12% for ST3Gal IV (n = 3), respectively. The mRNA
expression for other glycosyltransferases was aﬀected by 10%
or less inhibition (data not shown). Based on these results,
gene expression was suﬃciently and speciﬁcally suppressed
by transfection with siRNA. Moreover, siRNAs against
FUT VI and ST3Gal IV suppressed approximately 50% of
IL-1b-induced sLeX expression on HuH-7 cells. In contrast,
transfection with siRNAs against FUT IV and ST3Gal III into
HuH-7 cells did not aﬀect IL-1b-induced sLeX expression.
These data indicate that expression of sLeX on HuH-7-stimu-
lated with IL-1bis induced via enhance expression of FUT VI
and ST3Gal VI gene.4. Discussion
SLeX is biosynthesized by the reaction of a1,3-FT with a2,3-
sialylated N-acetyllactosamine, which is formed by the reac-
tion of a2,3-ST with N-acetyllactosamine. The following six
a2,3-STs have been cloned and characterized: ST3Gal I [16],
II [17], III [18], IV [19], V [20], and VI [21].The a2,3-STs show
substrate speciﬁcity, as ST3Gal III and IV can transfer a2,3-
linked sialic acid to N-acetyllactosamine to form a2,3-sialy-
lated N-acetyllactosamine.
The following six a1,3-FTs have also been cloned and char-
acterized: FUT III [22], IV [23], V [24], VI [25], VII [26] and IX
[27]. Of a1,3-FTs, FUT III, V, VI and VII can catalyze the
reaction of a1,3-linked Fuc with a2,3-sialylated N-acetyllactos-
amine to synthesize sLeX antigen [28].
FUT VI is especially important roles upon the sLeX biosyn-
thesis. The high expression of FUT VI is also essential to syn-
thesize sLeX in human colon carcinoma KM12 cells [29]. FUT
VI is believed to contribute to sLeX synthesis in the liver
[30,31]. Immuno-histochemical and Northern blot analysis
demonstrates that sLeX in primary liver cancer is mainly syn-
thesized by FUT VI and involved in cancer metastasis [32].
Fig. 5. Expression of ST3Gal III, IV, FUT IV and VI mRNA in HuH-7 stimulated with IL-1b. HuH-7 cells were treated with 100 U/ml IL-1b for 0,
2, 4, 7, 10, 24, and 48 h and mRNA expression levels in the cells were determined. Total RNA was extracted and synthesized into cDNA. ST3Gal III
(A) and ST3Gal IV (B), FUT IV (C) and FUT VI (D) mRNA expression levels were determined by real-time PCR using SYBR Green and speciﬁc
primers, and normalized to GAPDH mRNA levels. The data from three independent experiments are included at each time point; error bars deﬁne
the standard errors of each data set. Asterisks (*) indicate signiﬁcant diﬀerence (P < 0.05) compared with unstimulated cells.
Fig. 4. RT-PCR for glycosyltransferases and haptoglobin genes in HuH-7 cells stimulated with IL-1b. HuH-7 cells were treated with 100 U/ml IL-1b
for 0, 2, 4, 7, 10, 24, and 48 h and mRNA expression levels in the cells were determined. Total RNA was extracted and synthesized into cDNA.
Glycosyltransferases and haptoglobin mRNA expression levels were determined by RT-PCR using speciﬁc primer sets described in the text. Colo205
and HL-60 cells were used as positive controls (P) for FUT III and V and FUT VII in the PCR analysis.
K. Higai et al. / FEBS Letters 580 (2006) 6069–6075 6073The major a1,3-FT activity in human plasma is encoded by
FUT VI and a1,3-fucosylation on AGP is abolished in the mis-
sense mutation of FUT VI [33].
IL-1b stimulation of HuH-7 cells induced increases in sLeX
expression on AGP, as reported previously [14], and on the
HuH-7 cells in this study. Time-dependent expression of
a2,3-sialylated N-acetyllactosamine (MMA binding) and sLeX(CSLEX-1 binding) on HuH-7 cells stimulated with IL-1b re-
vealed that the increase in a2,3-sialylated N-acetyllactosamine
expression preceded the increase in sLeX expression (Fig. 1).
This result coincided well with the time-dependent increases
in a2,3-ST activities for N-acetyllactosamine and a1,3-FT
activities for a2,3-sialylated N-acetyllactosamine (Fig. 2).
Using RT-PCR (Fig. 3) and real-time PCR (Fig. 4), we
Fig. 6. sLeX expression on HuH-7 cells stimulated with IL-1b after
transfection of gene-speciﬁc siRNAs siRNAs against ST3Gal III, IV,
FUT IV and IV were transfected into the HuH-7 cells using
LipofectAMINE2000. These siRNA-transfected cells were stimulated
with 100 U/ml IL-1b for 48 h at 37 C and sLeX expression on the cells
was determined using anti-sLeX and POD-conjugated secondary
antibody. Each value is shown relative to non-siRNA-transfected
and IL-1b-stimulated cells, normalized to 1.0. The data from three
independent experiments are included at each time point; error bars
deﬁne the standard errors of each data set. Asterisks (*) indicate
signiﬁcant diﬀerence (P < 0.05) compared with non-transfected and
IL-1b-stimulated cells.
6074 K. Higai et al. / FEBS Letters 580 (2006) 6069–6075investigated time-dependent expression of ST and FUT genes.
FUT III, V and VII genes in HuH-7 cells were below the detec-
tion limits of RT-PCR; RT-PCR revealed that IL-1b stimula-
tion enhanced ST3Gal IV and FUT IV genes early (at 4 h) and
FUT VI late (at 24 h or more). Real-time PCR conﬁrmed alter-
ation of gene expression, early responses (2–7 h) of ST3Gal III,
ST3Gal IV and FUT IV gene expression and a late response
(>24 h) of FUT VI gene expression. Expression of N-acetylglu-
cosaminyltranseferase V is upregulated by increased stability
of the mRNA in mouse melanoma cells stimulated with trans-
forming growth factor b [34]. IL-1b stimulation also may in-
crease mRNA stability and upregulated ST3Gal IV and
FUT IV mRNA gene expression.
We have demonstrated that TNFa stimulation induced bi-
phasic increases in ST3Gal IV and FUT IV gene expression
in human colon adenocarcinoma-derived HT-29 cells; the in-
creases were suppressed by transfection of NF-jB-speciﬁc
siRNA (unpublished data). ST3Gal III, ST3Gal IV and FUT
IV gene expression may be regulated by direct IL-1b signaling
and transcription factors NF-jB or AP-1 in HuH-7 cells. The
mRNAs of ST3Gal IV consist of six isoform, type A1, A2, B1,
B2, B3 and BX [35]. Epithelial-cell-speciﬁc transcription of
ST3Gal IV is constitutively regulated by activator protein 2
(AP2) binding sites located within B3 promoter [36]. Since
the B3 promoter on 5 0 ﬂanking region of ST3Gal IV gene con-
tains AP2, mammary cell activating factor and c-Ets recogni-
tion elements [36], upregulation of ST3Gal IV mRNA byIL-1b may be induced by these transcriptional factors in hepa-
tocellular cell lines.
FUT VI gene expression is regulated by indirect IL-1b sig-
naling to transcriptional regulation or increased mRNA stabil-
ity. Transcriptional regulation and promoter structures of
FUT VI are not identiﬁed. We recently clariﬁed the transcrip-
tional regulation of FUT VI gene in hepatocellular carcinoma
HepG2 cells (to be submitted). Further investigation is neces-
sary to clarify its regulation in inﬂammation. Transfection of
siRNA revealed a large contribution of ST3Gal IV and FUT
VI and little or no contribution of ST3Gal III and FUT IV
to sLeX expression following stimulation with IL-1b in
HuH-7 cells.
In conclusion, IL-1b stimulation enhances ST3Gal IV and
FUT VI gene transcription and/or mRNA stability to increase
sLeX expression in the inﬂammatory liver.
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